Secondary Prevention in Younger vs. Older Coronary Heart Disease Patients—Insights from the German Subset of the EUROASPIRE IV Survey

[1] Members TF(2013)2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur Heart J 34 2949-3003

[2] Montalescot G(2009)Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 929-940

[3] Kotseva K(1997)A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events Eur Heart J 18 1569-1582

[4] Wood D(2001)Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme Eur Heart J 22 554-572

[5] De Backer G(2009)EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries Eur J Cardiovasc Prev Rehabil 16 121-137

[6] Kotseva K(2015)Secondary cardiovascular prevention in older adults: an evidence based review J Geriatr Cardiol 12 459-464

[7] Wood D(2005)Secondary prevention of coronary heart disease in elderly patients Am Fam Physician 71 2289-2296

[8] De Backer G(2012)Guiding principles for the care of older adults with multimorbidity: an approach for clinicians J Am Geriatr Soc 60 E1-E25

[9] Damluji AA(2005)Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes J Am Coll Cardiol 46 955-962

[10] Ramireddy A(2011)How applicable are clinical practice guidelines to elderly patients with comorbidities? Can Fam Physician 57 e253-e262

[1] Members TF(2013)2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur Heart J 34 2949-3003

[2] Montalescot G(2009)Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 929-940

[3] Kotseva K(1997)A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events Eur Heart J 18 1569-1582

[4] Wood D(2001)Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme Eur Heart J 22 554-572

[5] De Backer G(2009)EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries Eur J Cardiovasc Prev Rehabil 16 121-137

[6] Kotseva K(2015)Secondary cardiovascular prevention in older adults: an evidence based review J Geriatr Cardiol 12 459-464

[7] Wood D(2005)Secondary prevention of coronary heart disease in elderly patients Am Fam Physician 71 2289-2296

[8] De Backer G(2012)Guiding principles for the care of older adults with multimorbidity: an approach for clinicians J Am Geriatr Soc 60 E1-E25

[9] Damluji AA(2005)Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes J Am Coll Cardiol 46 955-962

[10] Ramireddy A(2011)How applicable are clinical practice guidelines to elderly patients with comorbidities? Can Fam Physician 57 e253-e262